PDS Biotechnology (PDSB) to Release Earnings on Thursday

PDS Biotechnology (NASDAQ:PDSB) is set to release its earnings data before the market opens on Thursday, November 14th. Analysts expect PDS Biotechnology to post earnings of ($0.29) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

PDS Biotechnology (NASDAQ:PDSB) last issued its earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.08. During the same quarter in the previous year, the company posted ($0.37) earnings per share. On average, analysts expect PDS Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PDS Biotechnology Trading Down 8.9 %

NASDAQ PDSB opened at $2.96 on Wednesday. PDS Biotechnology has a 52-week low of $2.53 and a 52-week high of $6.85. The firm has a 50-day moving average price of $3.25 and a 200 day moving average price of $3.29. The stock has a market capitalization of $108.99 million, a P/E ratio of -2.66 and a beta of 1.93. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.45.

Analyst Ratings Changes

PDSB has been the topic of several recent analyst reports. Alliance Global Partners upgraded shares of PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of PDS Biotechnology in a report on Thursday, October 24th. Finally, StockNews.com cut PDS Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $14.25.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.